Hospital Injectable Products · LP-191
Insulin 30/70 Injection
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-191Hospital Injectable Products
- Generic identity
- Insulin 30/70Injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-191
- Generic identity
- Insulin 30/70
- Presentation
- Injection
- Catalogue strength
- 100 IU/mL — 30% soluble human insulin with 70% isophane (NPH) human insulin; vial or cartridge
- Catalogue pack
- 10 mL vial or 3 mL cartridge; cold-chain carton
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Catalogue name: insulin 30/70.
- Dosage form: injection.
- Catalogue concentration: 100 IU/mL.
- Presentations: 10 mL vial or 3 mL cartridge; cold-chain carton.
Layer 02 · Unresolved product-specific fields
- Exact active insulin identities and the meaning/order of the 30/70 fractions.
- Whether the preparation is human insulin or an analogue premix.
- Cartridge/pen compatibility and device system.
- Approved dosing/timing, mixing/inspection instructions, storage limits and in-use period.
- Registration, manufacturing route and supply status.
Identity note
Numerical premix ratios are not enough to establish active identity. External human-insulin references provide only general safety context until the exact LP-191 components are controlled.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100 IU/mL | 10 mL vial | — | Cold-chain carton | Exact insulin components/fractions are not identified. |
| B | 100 IU/mL | 3 mL cartridge | — | Cold-chain carton | Exact insulin components/fractions and compatible delivery device are not identified. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
A premixed insulin combines components with different action profiles in a fixed formulation. The source calls this entry insulin 30/70, but does not identify the exact insulin type or explicitly define the fractions. Those details are clinically essential. A numeric mixture designation should never be treated as sufficient evidence that two insulin products have identical composition, timing or device compatibility.
Clinical context and therapeutic role
Insulin therapy requires an individualized diabetes-management plan, glucose monitoring and education about hypoglycaemia. A fixed mixture limits independent adjustment of its components and should be assessed against meals, activity and other treatment needs. The cited human-insulin information supplies general context only until the catalogue ingredient is fully specified. No switching method, injection schedule, glucose target or confirmation of product equivalence is provided here.
Selected safety context
Hypoglycaemia is the major immediate risk and can cause confusion, seizures or unconsciousness. Hyperglycaemia can follow inadequate delivery or use of the wrong product. Insulin can also cause local reactions, allergy and electrolyte changes. Illness, altered food intake, activity and kidney function affect management. Concentration, mixture identity and device errors are important preventable hazards. A trained professional should review changes rather than patients substituting products themselves.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The vial and cartridge presentations need separate compatibility and instruction checks. Confirm the insulin identity, fractions, concentration, physical characteristics and approved delivery devices. Do not assume that every 3 mL cartridge fits every insulin pen.
Insulin handling requires the product’s own instructions for unopened storage, transport, temperature excursions and time after first use. Do not infer these limits from another insulin. Keep product identity and concentration visible, and follow the prescribed process for inspection and preparation of the exact formulation.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Confirm exact insulin composition before clinical or procurement review. Assess the diabetes plan, monitoring and hypoglycaemia education, and verify device compatibility and supply conditions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Exact active-substance nomenclature and quantitative composition.
Finished-product specification and approved insulin label.
Cartridge/device compatibility evidence.
Cold-chain/stability and in-use data for the exact product.
Registration and manufacturing-site/release evidence.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: human insulin injection — general backgroundArchived source classification: government-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
| NHS: insulin/biphasic insulinArchived source classification: public health service medicine information | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-191.
Professional enquiries
Request product-specific evidence for LP-191.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.